Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy

HIV Clinical Trials

Volumn 12, Issue 4, 2011, Pages 222-227

  Palermo, Brandon ^a   Bosch, Ronald J ^b   Bennett, Kara ^b   Jacobson, Jeffrey M ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

body mass index; CD4 cell count; HIV infection; immune activation; obesity

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; HLA DR ANTIGEN;

ADULT; ANTIGEN EXPRESSION; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; OBESITY; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNDERWEIGHT; VIRUS INHIBITION;

ADULT; ANTI-RETROVIRAL AGENTS; BODY MASS INDEX; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HUMANS; LEPTIN; MALE; MIDDLE AGED;

EID: 80455129898     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/HCT1204-222     Document Type: Article

References (26)

1. Amorosa V, Synnestvedt M, Gross R, et al. A tale of 2 epidemics: The intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr. 2005;39:557-561.
2. Tilg H, Moschen AR. Adipocytokines: Mediators linking adipose tissue, infl ammation and immunity. Nat Rev Immunol. 2006;6:772-783.
3. Vendrell J, Broch M, Vilarrasa N, et al. Resistin, adiponectin, ghrelin, leptin, and proinfl ammatory cytokines: Relationship to obesity. Obes Res. 2004;12:962-971.
4. Hunt P, Martin J, Sinclair E, et al. T-cell activation is associated with lower CD4+ T-cell gains in HIV-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-1543.
5. Shor-Posner G, Campa A, Zhang G, et al. When obesity is desirable: A longitudinal study of the Miami HIV-1-infected drug users (MIDAS) cohort. J Acquir Immune Defic Syndr. 2000;23:81-88.
6. Jones CY, Hogan JW, Snyder B, et al. Overweight and human immunodeficiency virus (HIV) progression in women: Associations HIV disease progression and changes in body mass index in women in the HIV Epidemiology Research Study cohort. Clin Infect Dis. 2003;37: S69-S80.
7. Crum-Cianfl one NF, Roediger M, Eberly LE, et al; Infectious Disease Clinical Research Program HIV Working Group. Obesity among HIV-infected persons: Impact of weight on CD4 cell count. AIDS. 2010;24:1069-1072.
8. Bosch RJ, Bennett K, Collier AC, Zackin R., Benson CA. Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy. J Acquir Immune Defic Syndr. 2007;44: 268-277.
9. Smurzynski M, Collier AC, Koletar SL, RJBosch, Wu K, Bastow B, Benson CA. AIDS Clinical Trials Group longitudinal linked randomized trials (ALLRT): Rationale, design, and baseline characteristics. HIV Clin Trials. 2008;9: 269-282.
10. Lederman M, McKinnis R, Kelleher D, et al. Cellular restoration in HIV infected persons treated with abacavir and a PI: Age inversely predicts naive CD4 cell count increase. AIDS. 2000;14:2635-2642.
11. Kaufmann D, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper D. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS. 2002;16:359-367.
12. Grabar S, Le Moing V, Goujard L, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of HAART. Ann Intern Med. 2000;133:401-410.
13. Kaufman G, Perrin L, Pantaleo G, et al., Swiss HIV Cohort Study Group, CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: The Swiss HIV Cohort Study. Arch Intern Med. 2003;163:2187-2195.
14. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and HCV coinfection: The Swiss HIV Cohort Study. Lancet. 2000;356:1800-1805.
15. Erratum in Lancet. 2001;357:1536.
16. Ostrowski S, Katzenstein T, Thim P, Pedersen B, Gerstoft J, Ullum H. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving HAART. J Infect Dis. 2005;191:348-357.
17. Smith KY, Valdez H, Landay A, et al. Thymic size and lymphocyte restoration in HIV infected patients following 48 weeks of therapy with zidovudine, lamivudine and ritonavir. J Infect Dis. 2000;181:141-147.
18. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44:441-446.
19. Nowicki MJ, Karim R, Mack WJ, et al. Correlates of CD4+ and CD8+ lymphocyte counts in high-risk immunodeficiency virus (HIV)-seronegative women enrolled in the women's interagency HIV study (WIHS). Hum Immunol. 2007;68:342-349.
20. Womack J, Tien PC, Feldman J, et al. Obesity and immune cell counts in women. Metabolism. 2007;56:998-1004.
21. Zaldivar F, McMurray RG, Nemet D, Galassetti P, Mills PJ, Cooper DM. Body fat and circulating leukocytes in children. Int J Obes (Lond). 2006;30:906-911.
22. Fantuzzi G. Adipose tissue, adipokines, and infl ammation. J Allergy Clin Immunol. 2005;115:911-919.
23. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive- leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292-295.
24. Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reversed starvation-induced immunosuppression. Nature. 1998;394:897-901.
25. Farooqi IS, Matarese G, Lord GM, et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/ metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002;110:1093-1103.
26. Oral EA, Javor ED, Ding L, et al. Gorden. Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy. J Clin Endocrinol Metab. 2006;91:621-628.